Halozyme Therapeutics, Inc. research snapshot
HALO AI stock analysis currently reads Halozyme Therapeutics, Inc. as a high-quality drug delivery royalty platform with a commercially validated ENHANZE technology, growing royalty streams from partner products, and a fast-expanding Hypercon opportunity. As of the August 3, 2026 data cutoff, the latest verified close was $82.54 on July 31, with a market capitalization of about $9.79 billion and an AI score of 78 out of 100. The fundamental picture is strong: 2025 revenue reached $1.397 billion, Q1 2026 revenue grew 42% year over year, and management reiterated 2026 revenue guidance of $1.710 billion to $1.810 billion plus a new $1 billion repurchase authorization. The 2026 partner pipeline added Incyte, GSK, Vertex, and Oruka activity, and the stock now trades near its 52-week high. The main debate is whether partner launches, ENHANZE royalty durability, and Hypercon adoption can support the premium to trailing GAAP earnings while Halozyme manages debt, patent, regulatory, and concentration risk. This page is for information only and is not investment advice.
Current price
$82.54 at the July 31, 2026 close
Market cap
$9.79 billion
AI score
78 / 100
Rating
High-quality royalty platform with strong growth visibility, partner concentration, leverage, and valuation execution risk
Trend status
Constructive and near the 52-week high, above the 50-day and 200-day moving averages after a strong year-to-date advance
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | A high-margin drug delivery platform that earns royalties and product revenue when partner therapies use ENHANZE, while adding Hypercon and auto-injector technologies. | High |
| Moat | Commercial validation, regulatory know-how, patents, partner integration, and switching costs in drug development support a meaningful moat. Patent expiry and competing delivery technologies limit its width. | Medium-high |
| Management | CEO Helen Torley has led the company since 2014 and has built a partner-led royalty model. 2025 acquisitions of Elektrofi and Surf Bio expanded the platform but added debt and execution demands; a new CFO took office in June 2026. | Medium-high |
| Financial trend | Revenue grew from $443.3 million in 2021 to $1.397 billion in 2025. Q1 2026 revenue rose 42% to $376.7 million and net income rose 27% to $150.0 million, with TTM free cash flow of about $667.7 million. | High |
| Valuation | At $82.54, HALO trades at about 29.1x TTM GAAP EPS and 14.7x TTM free cash flow. The 2026 non-GAAP EPS guidance midpoint of $8.00 implies a much lower forward multiple, but that guidance is not GAAP earnings. | Medium-high |
| Technical trend | The stock is above the 50-day average of $74.31 and 200-day average of $69.86, with RSI near 64.85 and the price about 2% below the $84.44 52-week high. Momentum is positive but extended. | Medium-high |
| Risk level | Risk is medium-high because royalties depend on partner commercialization, patents and approvals, while the balance sheet carries about $2.15 billion of debt and the stock has short interest of about 11% of shares outstanding. | High |
| AI confidence | The public record is strong enough for a useful descriptive analysis, but forward outcomes remain sensitive to partner milestones, pricing policy, patent disputes, and valuation assumptions. | High data confidence |
| Investment certainty | The existing ENHANZE royalty engine is understandable and cash generative, but a durable margin of safety requires continued launches and growth beyond the current guidance cycle, especially near the 52-week high. | Medium |
HALO AI stock forecast
The HALO AI stock forecast is scenario math, not a price promise. It starts with the company's 2026 non-GAAP diluted EPS guidance midpoint of $8.00 rather than trailing GAAP EPS of $2.84. The required financial_rigor.py three-scenario calculation used 15%, 8%, and negative 12% annual EPS growth with terminal P/E assumptions of 18x, 14x, and 8x. The resulting mechanical three-year reference values were about $219, $141, and $44. Because the starting EPS is management's non-GAAP guidance and not realized GAAP earnings, and because the stock already trades near its 52-week high, the page presents wider ranges around those outputs.
$195 to $225
More likely if royalty revenue remains above 30% growth, DARZALEX FASPRO and VYVGART Hytrulo keep expanding, new ENHANZE and Hypercon deals such as Incyte, GSK, Vertex, and Oruka progress toward approvals, and buybacks reduce the share count without weakening the balance sheet.
$125 to $150
More likely if 2026 guidance is achieved, royalty growth moderates after the current launch cycle, new deals create long-dated optionality, and investors value normalized non-GAAP earnings near a mid-teens multiple.
$40 to $55
More likely if a major partner product slows, approvals or milestones are delayed, patent or pricing pressure reduces royalties, Hypercon investments fail to scale, or debt and the GAAP to non-GAAP earnings gap drive a sharp multiple reset from a stock trading near its high.
HALO AI technical analysis
HALO AI technical analysis is constructive as of the August 3, 2026 data cutoff, but the stock is near its 52-week high. The latest verified close was $82.54 on July 31, 2026. The stock is above its 50-day and 200-day moving averages, with a 52-week range of $58.53 to $84.44. A continuation above the recent high would need volume confirmation, while a pullback toward the moving averages would test whether the uptrend is being accumulated or simply retraced.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $82.54 | StockAnalysis closing price on July 31, 2026. The after-hours quote was $82.57. |
| Near support | $74.00 to $75.00 | The 50-day moving average was $74.31. A hold in this zone would keep the intermediate trend constructive. |
| Deeper support | $69.50 to $70.50 | The 200-day moving average was $69.86. A decisive close below this area would weaken the longer-term setup. |
| Near resistance | $83.50 to $84.44 | This zone contains recent price highs and the reported 52-week high of $84.44. |
| 52-week range | $58.53 to $84.44 | StockAnalysis and Nasdaq market data range as of the July 31, 2026 close. |
| Moving averages | 50-day $74.31; 200-day $69.86 | Both averages were below the latest close. Values were verified from StockAnalysis on August 2, 2026. |
| Momentum | Positive, RSI 64.85 | Momentum is positive and approaching overbought territory. It does not establish a fundamental buy signal. |
| Volume | 1.56 million shares; 1.73 million 20-day average | The July 31 session volume was below the recent average, so a new 52-week high would need stronger participation for confirmation. |
| Invalidation | Decisive close below $70.00 | A sustained break below the 200-day average would invalidate the constructive intermediate trend framework. |
HALO AI trading strategy
The HALO AI trading strategy below is a research framework, not personal advice. It combines price confirmation with partner-product monitoring, valuation discipline, and explicit invalidation conditions because the stock can reprice when a large royalty stream or regulatory milestone changes, and it is currently trading near its 52-week high.
Watch for a close above the $84.44 52-week high with volume above the recent average, then verify that royalty growth, partner approvals such as Incyte, GSK, Vertex, and Oruka, and 2026 guidance remain intact.
Define the invalidation before entry. A failed breakout followed by a close below $75, or a decisive break below $70, would show that price confirmation has failed.
If HALO pulls back toward the $70 to $75 moving-average zone without a thesis break, compare the price with TTM free cash flow, 2026 guidance, royalty concentration, and net debt before considering a rebound framework.
Do not average down solely because the stock is below a recent high. Reassess if a partner product misses expectations, guidance is cut, or the price closes below the 200-day average.
Track DARZALEX FASPRO, VYVGART Hytrulo, Phesgo, royalty revenue, new ENHANZE and Hypercon agreements including Incyte, GSK, Vertex, and Oruka, product approvals, patent developments, debt repayment, the new $1 billion buyback, and the GAAP to non-GAAP earnings bridge.
Treat management guidance as a scenario input, not a guarantee. Update the model after each earnings release, major partner announcement, regulatory decision, or material patent event. Q2 2026 results are scheduled for August 6, 2026.
Investment research summary
Customers pay Halozyme because ENHANZE can help convert intravenous biologics to faster subcutaneous delivery, reduce treatment burden, and support differentiated formulations. Halozyme licenses the technology to biopharmaceutical partners and earns royalties, product sales, milestones, and development revenue. The economic engine is a small platform supporting multiple partner products rather than a single internally marketed drug.
The strongest moat is commercial and regulatory know-how around rHuPH20, supported by patents, partner integration, accumulated clinical evidence, and a record of approved products. Halozyme reported thirteen collaborations and ten approved products using ENHANZE in its 2025 10-K. The moat is not permanent: patent expiry, competing delivery platforms, partner bargaining power, and safety or regulatory issues could narrow it.
The thesis fails if a key royalty product loses momentum, a partner terminates or underperforms, an approval or milestone is delayed, a patent challenge weakens protection, or rHuPH20 safety and manufacturing issues affect several products at once. The 2025 acquisitions of Elektrofi and Surf Bio also add integration risk, amortization, debt, and a need to prove that Hypercon can become a durable second growth platform.
CEO Helen Torley has led Halozyme since 2014 and has focused the company on partner-led ENHANZE royalties, commercial products, and selective platform expansion. The new $1 billion repurchase authorization and the plan to buy back at least $400 million in 2026 show confidence in cash generation, but capital allocation must be weighed against about $2.15 billion of debt and the future funding needs of Hypercon and Surf Bio.
Subcutaneous delivery is part of a broader shift toward lower-burden, more convenient administration of biologics and potential home treatment. Halozyme benefits when large pharmaceutical companies move established therapies from infusion centers to shorter injections. The opportunity is meaningful, but adoption depends on clinical evidence, payer economics, manufacturing, regulatory approvals, and partner execution rather than on technology alone.
At $82.54, HALO trades around 29.1x TTM GAAP EPS, 6.5x sales, and 14.7x TTM free cash flow. The valuation looks more moderate against the company's $7.75 to $8.25 2026 non-GAAP EPS guidance, but that comparison excludes amortization, acquisition-related items, and other adjustments. With the stock near its 52-week high, the margin of safety therefore depends on converting current royalty growth and future deal activity into durable cash earnings while reducing balance-sheet risk.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| HALO price and market snapshot | $82.54 close on July 31, 2026; $9.79 billion market cap; 118.61 million shares outstanding; 52-week range $58.53 to $84.44 | StockAnalysis HALO statistics, cross-checked to Nasdaq historical data | August 3, 2026 |
| FY2025 revenue | $1.397 billion, up 38% year over year | Halozyme 2025 Form 10-K, cross-checked to StockAnalysis financials | August 3, 2026 |
| FY2025 royalty revenue | $867.8 million, up 52% year over year | Halozyme Q4 and FY2025 earnings release and 2025 Form 10-K | August 3, 2026 |
| FY2025 net income and free cash flow | $316.9 million GAAP net income; about $644.6 million free cash flow, calculated as $651.6 million operating cash flow less $7.0 million capital spending | Halozyme 2025 Form 10-K, cross-checked to StockAnalysis financials | August 3, 2026 |
| Q1 2026 operating results | $376.7 million revenue, up 42%; $240.7 million royalty revenue, up 43%; $150.0 million net income, up 27%; GAAP diluted EPS $1.22; non-GAAP diluted EPS $1.60 | Halozyme Q1 2026 results press release and Form 10-Q | August 3, 2026 |
| TTM revenue, earnings and free cash flow | $1.508 billion revenue, up 39%; $348.8 million net income; about $667.7 million free cash flow; TTM EPS about $2.84 | StockAnalysis HALO financial statements (TTM ending March 31, 2026) | August 3, 2026 |
| Liquidity and debt | $318.6 million cash plus marketable securities and approximately $2.15 billion total debt at March 31, 2026 | Halozyme Q1 2026 Form 10-Q, cross-checked to StockAnalysis balance sheet | August 3, 2026 |
| 2026 management guidance | $1.710 billion to $1.810 billion total revenue; $1.130 billion to $1.170 billion royalty revenue; $1.125 billion to $1.205 billion adjusted EBITDA; $7.75 to $8.25 non-GAAP diluted EPS | Halozyme Q1 2026 results and guidance update | August 3, 2026 |
| Share repurchase program | New $1 billion authorization to repurchase by December 31, 2028, with an expectation of buying back at least $400 million in 2026 | Halozyme Q1 2026 results press release | August 3, 2026 |
| Analyst consensus | Consensus Buy from 9 analysts; average price target $86.89, with a reported range of $70 to $96 | StockAnalysis HALO forecast, S&P Global and TipRanks data | August 3, 2026 |
| Technical reference | $58.53 to $84.44 52-week range; 50-day moving average $74.31; 200-day moving average $69.86; RSI 64.85; 20-day average volume 1.73 million | StockAnalysis HALO statistics, with Nasdaq historical price and volume data | August 3, 2026 |
| Platform and partner base | Thirteen ENHANZE collaborations and ten approved products reported in the 2025 Form 10-K; 2026 updates added Incyte, GSK, Vertex, and Oruka collaboration activity; Q2 2026 earnings scheduled for August 6, 2026 | Halozyme 2025 Form 10-K, Q1 2026 results update, and July 2026 Incyte announcement | August 3, 2026 |
This HALO AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 3, 2026 and can be wrong. Technical levels can change with each trading session.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
